Psoriasis is Mediated by a Cutaneous Defect Triggered by Activated Immunocytes: Induction of Psoriasis by Cells with Natural Killer Receptors  by Gilhar, Amos et al.
Psoriasis is Mediated by a Cutaneous Defect Triggered by
Activated Immunocytes: Induction of Psoriasis by Cells with
Natural Killer Receptors
Amos Gilhar, Yehuda Ullmann, Hedviga Kerner,* Bedia Assy, Raya Shalaginov, Sima Sera®movich, and
Richard S. Kalish²
Skin Research Laboratories, Flieman Medical Center and Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel;
*Department of Pathology, Rambam Medical Center, Technion Institute of Technology, Haifa, Israel; ²Department of Dermatology, State University
of New York at Stony Brook, U.S.A.
This study was performed to ask whether psoriasis is
a unique pathologic response of epidermis of psoria-
tic patients, or cells with natural killer receptors can
induce psoriatic changes in skin from nonpsoriatic
donors. Human nonlesional skin from ®ve psoriatics,
as well as from seven nonpsoriatics was grafted on to
beige-SCID mice. Lymphocyte lines with natural
killer activity, and mixed natural killer, natural killer
T cell phenotype, were generated by culture of per-
ipheral blood mononuclear cells from both psoriatic,
and normal donors, in 100 U interleukin-2 per ml for
14 d. Natural killer cells were injected into the
human skin grafts, and the grafts were harvested
after 4 wk. Injection of natural killer cells from psor-
iatic donors into autologous nonlesional psoriatic
skin resulted in classic psoriasis histology with a sig-
ni®cant increase in epidermal thickness, and prolifer-
ation, as well as expression of epidermal human
leukocyte antigen DR, intercellular adhesion mol-
ecule-1, CD1d, and K-16. Superantigen stimulation
was not necessary. In contrast, injection of natural
killer cells from normal donors into autologous nor-
mal skin did not induce the histology of psoriasis,
but that of psoriasiform dermatitis. This is a nonspe-
ci®c reaction pattern. These grafts also exhibited a
signi®cant increase in epidermal thickness, and pro-
liferation. Differences from psoriasis included mild
epidermal edema (spongiosis), hypergranulosis,
irregular elongation of rete ridges, and lack of thin-
ning of the suprapapillary plate. Injection of allo-
geneic natural killer cells into grafts also resulted in
psoriasiform dermatitis, regardless of the source of
natural killer cells, or skin. Psoriasis induction by
cells with natural killer receptors appears to be
dependent upon the source of skin. This suggests
that psoriasis results from a cutaneous defect that is
triggered by an autoimmune activation. Key words:
human/natural killer lymphocytes/psoriasis/SCID mice/
skin. J Invest Dermatol 119:384±391, 2002
T
here is now considerable evidence that psoriasis is
triggered by lymphocytes. This evidence includes the
ability to clear psoriasis with a fusion protein targeted
to interleukin (IL)-2 receptors (Gottlieb et al, 1995), as
well as the ability to induce (Boehncke et al, 1996;
Wrone-Smith and Nickoloff, 1996; Boehncke et al, 1997), and
maintain (Gilhar et al, 1997) psoriasis in human skin grafted to
SCID mice, by the injection of activated lymphocytes. Features of
psoriatic epidermis that have been induced, or maintained in the
above studies include, epidermal thickness, labeling index,
abnormal differentiation, and keratinocyte expression of inter-
cellular adhesion molecule (ICAM-1), and HLA-DR. Inhibitors of
T cell activation and costimulation are also able to clear psoriasis,
further supporting the link between lymphocyte activation and
psoriasis (Gottlieb et al, 2000a, b). Previous experimental work with
psoriasis has focused on the function of T lymphocytes, activated
with bacterial superantigens.
The potential role of natural killer cells in psoriasis was ®rst
suggested by Nickoloff et al (1999). Using the human skin explant/
SCID mouse system, they found that injection of allogeneic natural
killer cells from psoriatic donors induced changes similar to psoriasis
in normal skin from nonpsoriatic donors. The suggested role for
natural killer cells does not con¯ict with the previous SCID mouse
data, as superantigen and IL-2 stimulation of T cells induces natural
killer activity. Nickoloff et al subsequently characterized one such
CD94+/CD161+ natural killer T cell line that was generated by
stimulation of lymphocytes of a psoriatic patient with IL-2 plus
superantigen. This natural killer line induced psoriasis-like
histology upon injection into nonlesional skin of psoriasis patients
(Nickoloff et al, 2000). The interaction of natural killer T cells with
epidermis may be mediated by keratinocyte CD1d expression
(reviewed in Nickoloff, 2000b). Psoriatic epidermis expresses high
levels of CD1d, and the natural killer T cells produce interferon
(IFN)-g upon incubation with CD1d-positive keratinocytes, which
is inhibited by anti-CD1d.
This study was performed to ask whether psoriasis is a unique
pathologic response of epidermis of psoriatic patients, or whether
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autologous natural killer cells can induce psoriatic changes in skin
from nonpsoriatic donors. The activity of autologous natural killer
cells also needed to be tested, as the Nickoloff studies (Nickoloff
et al, 1999) made use of allogeneic lines, which raises the possibility
of a graft versus host response. An additional aim of this study was
to determine whether induction of psoriasis is a general property of
natural killer cells.
It was found that autologous natural killer cells (natural killer
cells plus natural killer T cells) were able to induce psoriasis in
noninvolved skin of psoriasis donors. In contrast, autologous
natural killer cells induced psoriasiform dermatitis-like changes in
the skin of nonpsoriatic donors. Psoriasiform dermatitis differs from
true psoriasis, and is a common reaction pattern of skin to multiple
insults ranging from atopic dermatitis, to fungal infection. The data
suggest that psoriasis is dependent upon a primary cutaneous defect
that is triggered by immunocytes.
MATERIALS AND METHODS
Animals C.B-17/IcrHsd-scid-bg (beige-SCID) mice (Harlan
Laboratories Ltd, Jerusalem, Israel), 2±3 mo of age, were used in this
study. The mice were raised in the pathogen-free animal facility of the
B. Rappaport Faculty of Medicine, Technion-Israel Institute of
Technology. Animal care and research protocols were in accordance
with institutional guidelines, and approved by the institutional committee
on animal use.
Patients After receiving approval of the institutional ethics committee,
seven healthy nonpsoriatic donors, and ®ve psoriatic patients were
included in this study. All patients had classic plaque psoriasis. None of
the patients were treated. Non-lesional psoriatic skin was obtained from
the thighs of each patient by electrical dermatome (Brown 666). Normal
skin obtained from seven nonpsoriatic subjects who underwent surgical
procedures at the Plastic Department of the Rambam Medical Center,
Haifa, served as a control group.
Culture of cells with natural killer activity and receptors Peripheral
blood mononuclear cells (PBMC) were isolated from both psoriatic and
nonpsoriatic donors by centrifugation on Ficoll/Hypaque (Pharmacia,
Amersham Pharmacia Biotech, Uppsala, Sweden). The PBMC were then
cultured with 100 U IL-2 per ml (Pepro Tech Inc, Rocky Hill, NJ) in
medium composed of RPMI 1640, 10% human AB serum (Sigma, St.
Louis, MO), 1% glutamine, 1% antibiotics (media components;
Biological Industries, Kibbutz Beit Haemeck, Israel). Medium was
changed as needed. After 21 d the cells were characterized and injected
into human skin explants on beige-SCID mice. Cultured cells were
phenotyped by cyto¯uorograph (Becton Dickinson, San Jose, CA) with
the following antibodies: anti-CD3, anti-CD4, anti-CD8 (Becton
Dickinson), as well as natural killer markers anti-CD56 (Becton
Dickinson), CD94, CD158a, CD158d (Serotec, Oxford, U.K.), and
CD161 (Pharmingen, San Diego, CA). Murine IgG was used as a
control.
Natural killer cytotoxicity assay Cultured cells were assayed for
natural killer activity by cytotoxicity on K562 targets using a standard
51Cr release assay (Kalish et al, 1988).
Skin transplantation and injection of lymphocytes Skin
transplantation was performed as described previously (Gilhar et al, 1993;
1995). Skin from psoriasis and non-psoriasis donors was transplanted
onto four mice, which were divided into four groups (one mouse each)
and injected with T-cells 4 wk following skin engraftment. Mice were
divided as follows: (i) not injected control; (ii) autologous natural killer
cells; (iii) allogeneic natural killer cells from psoriatic donors;
(iv) allogeneic natural killer cells from normal donors. Four weeks after
lymphocyte injection (8 wk after engraftment) the grafts were harvested.
Grafts were analyzed by histology and immunohistochemistry. Mice
were divided as follows: (i) psoriatic skin not injected control; (ii)
psoriatic skin, autologous psoriatic natural killer cells; (iii) psoriatic skin,
allogeneic natural killer cells; (iv) psoriatic skin, allogeneic normal natural
killer cells; (v) normal skin not injected control; (vi) normal skin,
autologous normal natural killer cells; (vii) normal skin, allogeneic
psoriatic natural killer cells; and (viii) normal skin, allogeneic normal
natural killer cells. Natural killer cells were suspended in complete
medium (RPMI 1640, 10 human AB serum, 1% glutamine, 1%
antibiotics, 100 U IL-2 per ml), at 10 3 106 cells per ml. Natural killer
cells were injected intradermally in 0.7 ml (700,000 cells).
Determination of epidermal thickness Histologic assessment of the
grafts was performed by light microscopy both before and after
transplantation. Evaluation was performed by two blinded observers, one
who was not aware of the design of the study. Epidermal thickness was
determined with an ocular micrometer, at a minimum of 50 points along
the epidermis selected to represent points of maximal and minimal
thickness. Thickness of the suprapapillary plate was similarly measured at
50 points for each sample.
Immunohistochemical staining and IFN-g enzyme-linked
immunosorbent assay Monoclonal antibodies to human antigens
used were as follows for immunohistochemistry: anti-cytokeratin 16
(Sigma), anti-HLA-DR (Becton Dickinson), anti-CD54 (ICAM-1)
(Biodesign, ME, USA), and Ki-67 (Zymed Laboratories, San Francisco,
CA). Puri®ed murine IgG was used as a control for the above
antibodies. Rat anti-mouse neutrophil antibody obtained from Serotec.
Puri®ed rat IgG was used as the control for the above antibody.
Immunohistochemistry was performed on OCT embedded specimens
with a biotin±avidin system (Vectostain, Vector Laboratories,
Burlingame, CA). The human IFN-g enzyme-linked immunosorbent
assay kit was obtained from Endogen (Woburn, MA).
Statistical analysis All statistical comparisons were performed using
ANOVA, Tukey±Kramer multiple comparison tests. p < 0.05 was
considered statistically signi®cant.
RESULTS
Properties of natural killer, and natural killer T cells
generated by culture of PBMC with IL-2 Culture of
PBMC with 100 U IL-2 per ml generated natural killer activity
as manifest both by cytotoxicity against K562 targets, and
phenotype. Cytotoxicity for K562 cells was 76%, 73%, and 66%
at effector±target ratios of 1:50, 1:25, and 1:12.5, respectively (SD
of 11, 13, and 15). IL-2-stimulated lymphocytes also expressed a
mixed natural killer, and natural killer T cell phenotype as
demonstrated by increased expression of CD56, CD94, CD158a,
and CD158b (Table I).
IFN-g levels in culture supernatant of natural killer cells were
assayed by enzyme-linked immunosorbent assay for both psoriatic
and normal natural killer cell lines. The level of IFN-g production
was equivalent between normal natural killer cell lines (mean
3.1 ng per ml, SD 2.2), and psoriatic natural killer cell lines (mean
2.2 ng per ml, SD 1.2).
Injection of autologous natural killer cell lines into
nonlesional psoriatic skin induces histology of a psoriatic
plaque Nonlesional skin grafts from ®ve psoriasis patients were
injected with autologous natural killer cell lines. The grafted
nonlesional skin developed histologic changes classic for a psoriasis
plaque (Fig 1). These changes included parakeratosis with absence
of granular layer, hyperkeratosis, epidermal thickening (acanthosis)
Table I. Distribution of markers (%) of PBMC and lines
with natural killer cell activity after culture with IL-2a
Markers
Control donors Psoriatic donors
Initial Final Initial Final
CD3 70 6 9 33 6 17 65 6 9 35 6 16
CD4 35 6 10 10 6 10 37 6 4 11 6 7
CD8 30 6 11 56 6 22 28 6 4 53 6 22
CD16 10 6 8 31 6 17 11 6 9 20 6 11
CD56 14 6 5 50 6 21 18 6 9 45 6 17
CD94 15 6 8 54 6 15 15 6 6 49 6 18
CD158a 6 6 3 9 6 9 5 6 4 12 6 14
CD158b 8 6 3 15 6 5 8 6 7 16 6 13
CD161 17 6 8 35 6 8 15 6 4 9 6 6
aPBMC from psoriatic, and nonpsoriatic donors cultured with 100 U IL-2 per
ml. Phenotypes were determined by cyto¯uorograph both prior to, and after cul-
ture.
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with regular elongation of rete ridges, suprapapillary epidermal
thinning, Munro's microabcesses, and minimal or no
intraepidermal edema (spongiosis). Munro's microabcesses were
observed in the human epidermis, with neutrophils of mouse
origin. Murine derivation of the neutrophils was con®rmed by
immunohistochemistry staining (Fig 2). Vascular dilatation
associated with a perivascular lymphocytic in®ltrate was noted in
the papillary dermis. Histologic features of the grafts are listed in
Table II.
There was a signi®cant increase in epidermal thickness (p < 0.05
by Tukey±Kramer multiple comparison test) of injected nonpsor-
iatic skin compared with control skin (Fig 3). This was associated
with a signi®cant increase (p < 0.05 by ANOVA) in the epidermal
proliferation index as measured by Ki-67 staining (Fig 4).
Immune activation of the epidermis was evidenced by diffuse
expression of HLA-DR (Fig 2), and ICAM-1. This was accom-
panied by loss of proper epidermal differentiation, with expression
of K-16 cytokeratin, and Ki-67 as is observed in psoriasis (Fig 2).
The above antigens were strongly expressed with diffuse staining
over at least 50% of the epidermis in grafts from three of three
donors. Control, noninjected grafts expressed focal HLA-DR, and
ICAM-1 in grafts from one of three donors.
Injection of autologous natural killer cell lines into skin from
nonpsoriatic normal donors induces psoriasiform
dermatitis, which is not psoriasis The changes seen in skin
from seven normal donors injected with autologous natural killer
cells included signi®cant epidermal thickening (acanthosis),
Figure 1. Psoriasis patient nonlesional skin
grafted to beige-SCID mice and injected
with natural killer cells. Results are shown for
two donors, not injected, injected with
autologous (psoriasis) natural killer cells, allogeneic
psoriasis natural killer cells, and allogeneic normal
(nonpsoriasis) natural killer cells. Scale bar: 50 mm.
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hyperkeratosis, parakeratosis, along with a dermal lymphocytic
in®ltrate; however, the histology differed from psoriasis because of
the presence of mild intraepidermal edema (spongiosis), irregular
acanthosis, retention of the granular layer, and lack of thinning of
the suprapapillary plate (Figs 5 and 6, and Table II). Many of the
grafts also exhibited hypergranulosis, in contrast to the loss of the
granular layer observed in psoriasis. The above data are listed in
Table II. Injected grafts exhibited signi®cant increases in
epidermal thickness (Fig 3) and the proliferative index (Fig 4), as
was observed with psoriasis grafts; however, in contrast to the
psoriasis grafts injected with autologous natural killer cells, there
was no thinning of the suprapapillary plate (Table III).
Immunohistology of the psoriasiform dermatitis was similar to
that of psoriasis with expression of HLA-DR, ICAM-1, and
cytokeratin 16 (Fig 2). These changes were those of psoriasiform
dermatitis, a common reaction pattern exhibited in a wide variety
of in¯ammatory skin diseases ranging from atopic dermatitis, to
fungal infections.
Injection of allogeneic natural killer cells from normal or
psoriatic donors resulted in psoriasiform dermatitis, not
psoriasis Skin from normal controls, and nonlesional psoriasis
skin was injected with allogeneic natural killer cells derived both
from normal and psoriasis donors (Figs 1 and 5). Regardless of the
source of skin, or natural killer cells, psoriasiform changes were
observed similar to those described above for natural killer cells
from normal donors (Figs 5 and 6); however, the ®ndings were
distinct from psoriasis. Features differing from psoriasis included
irregular acanthosis (epidermal thickening), hypergranulosis
(increased granular layer), and mild spongiosis (epidermal edema)
(Table II). These grafts also lacked thinning of the suprapapillary
plate (Table III).
Epidermal expression of CD1d Psoriatic noninvolved skin
had diffuse expression of CD1d prior to injection of natural killer
cells (three of three), and maintained this expression following their
injection (Fig 2), con®rming the ®ndings of Nickoloff et al (1999,
2000). Skin from nonpsoriatic donors either did not express CD1d,
or showed weak diffuse staining (three of six). Injection of natural
killer cells from autologous, or allogeneic donors resulted in strong
diffuse expression of CD1d in six of six grafts.
DISCUSSION
The histologic changes of psoriasis were induced by injection of
lymphocytes with natural killer receptors into autologous non-
involved skin from psoriatic donors grafted on to beige-SCID
mice. This effect of natural killer cells was not dependent upon
stimulation with superantigen. In contrast, injection of natural killer
cells from seven control nonpsoriatic donors into autologous
control skin grafts resulted in the changes of psoriasiform dermatitis,
which differed signi®cantly from psoriasis. Psoriasiform dermatitis is
a common, nonspeci®c reaction pattern, which is shared by many
conditions as varied as atopic dermatitis and fungal infections. The
distinction from true psoriasis is important, because this model has
been widely promoted as a model for psoriasis. The principal
®nding is that skin from psoriatic patients reacts differently in
response to natural killer cells. It is proposed that psoriasis results
from a cutaneous defect that is triggered by lymphocyte activation.
A primary cutaneous defect in psoriasis was suggested by the
athymic nude mouse grafting studies of Krueger et al (1981).
Involved and noninvolved psoriatic skin was grafted on to nude
mice, and compared with grafts of skin from normal donors.
Initially, the DNA labeling index of involved psoriatic skin was
grossly elevated compared with either uninvolved skin of psoriatic
donors, or normal skin from normal donors. After grafting to nude
mice, the labeling index of involved psoriatic skin decreased,
whereas the labeling index of noninvolved psoriatic skin increased,
until they were equivalent, but signi®cantly higher than that of
grafted normal skin. This suggests that there is a primary defect in
psoriatic skin. As epidermis and dermis interact, it is not possible
from these experiments to conclude whether the defect is primary
in epidermis or dermis.
The initial ®nding that natural killer cells can induce psoriasis was
made by Nickoloff et al (1999, 2000), who reported on a single
natural killer line that induced psoriasis-like changes in an
allogeneic human skin explant/SCID mouse transfer system. Our
Figure 2. Immunohistochemistry staining. (A) Control, noninjected
psoriasis skin graft stained for HLA-DR, demonstrating staining only on
Langerhans dendritic cells. The remaining ®gures are of psoriatic skin
grafts injected with autologous natural killer cells, and stained for (B)
HLA-DR, (C) K-16, (D) CD1d, (E) Ki-67, and (F) anti-murine
neutrophil antibody Scale bars: (A, B, C, E) 20 mm, (D, E) 10 mm.
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®ndings, however, differ from those of Nickoloff et al, who
reported that natural killer cells induce psoriasis in skin from
normal, nonpsoriatic donors. In contrast, we have found that
natural killer cells induce psoriasis in nonlesional skin from psoriatic
donors, and psoriasiform dermatitis in skin from normal donors.
Furthermore, injection of allogeneic natural killer cells from either
psoriatic, or normal donors, induced psoriasiform dermatitis. One
difference between the experimental systems used is that our mice
were beige-SCID, and Nickoloff et al used SCID mice. The beige-
SCID mice have less natural killer activity. Furthermore, this report
demonstrates that bacterial superantigens do not play any unique
part in the activation of natural killer cells to induce psoriasis, as we
generated natural killer cells with IL-2 alone. We have previously
reported that lymphocytes with natural killer activity, activated by
the same protocol used for this study, are nonspeci®cally cytotoxic
for keratinocytes, suggesting natural killer recognition of keratino-
cytes (Kalish, 1989). Our model differs from the Nickoloff model
(Nickoloff et al, 1999, 2000; Nickoloff, 2000a,b) in that the
Table II. Histologic features of psoriasis explants
Source of
skin
Source of
natural killer cells
Granular layer
present
Munro's
microabscess present
Spongiosis
present
Psoriatic Autologous psoriatic 0/5a 3/5a 0/5a
Psoriatic Allogeneic normal 4/5 0/5 5/5
Normal Autologous normal 7/7 0/7 7/7
Normal Allogeneic normal 7/7 0/7 3/7
ap < 0.05 in comparison with normal skin, autologous natural killer cells, by c2.
Figure 3. Epidermal thickness of grafts injected with natural
killer cells from autologous, or allogeneic donors. Grafts were
obtained from both psoriatic, and nonpsoriatic donors.
Figure 4. Ki-67 staining index (proliferation marker) of grafts
injected with natural killer cells from autologous, or allogeneic
donors. Grafts were obtained from both psoriatic, and nonpsoriatic
donors.
Table III. Thickness of suprapapillary platea
Source skin
explant
Source of
natural killer cells
Thickness
suprapapillary
plate (p) by ANOVA
Psoriasis skin Autologous psoriasis natural killer 17 6 1 mm Reference
Psoriasis skin no natural killer cells injected 33 6 5 mm p < 0.01
Psoriasis skin Allogeneic psoriasis natural killer 30 6 1 mm p < 0.001 by
t-test (n = 2)
Psoriasis skin Allogeneic normal natural killer 31 6 9 mm p < 0.01
Normal skin no natural killer cells injected 23 6 2 mm p < 0.001 by
t-test
Normal skin Allogeneic psoriasis natural killer 29 6 2 mm p < 0.05
Normal skin Allogeneic normal natural killer 27 6 7 mm p < 0.05
Normal skin Autologous normal natural killer 30 6 5 mm p < 0.01
aFor psoriasis skin, n = 5 donors. For normal skin, n = 7 donors.
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lymphocytes with natural killer receptors were generated by IL-2
alone, in the absence of bacterial superantigen. In the absence of
superantigen stimulation, cells with natural killer receptors were
unable to induce psoriasis in skin from nonpsoriatic donors.
In addition to pure natural killer cells, natural killer receptors are
present on subsets of T cells (natural killer T). Natural killer T cells
expressing CD161 tend to have T cell receptor expression restricted
to Va16, and recognize the glycolipid, a-galactosylceramide
presented by CD1d (Matsuda et al, 2000). These CD161+ natural
killer T cells produce IFN-g on triggering (Takahashi et al, 2000).
Keratinocytes in psoriatic skin lesions express high levels of CD1d,
and keratinocyte CD1d is capable of inducing natural killer cells to
aggregate, and secrete IFN-g (Bonish et al, 2000). Expression of
CD1d by psoriatic skin has been con®rmed in our study. In
contrast, CD1d is expressed at low levels in noninvolved skin. IFN-
g production by natural killer or natural killer T cells may have
direct relevance to the induction of psoriasis.
Psoriasis has an association with HLA-Cw6 (Bhalerao and
Bowcock, 1998; Brazzelli et al, 2000). There are two subclasses of
natural killer cell KIR receptors (KIR2D) with speci®city for HLA-
C. KIR2DL1 recognizes HLA-Cw2, 4, 5, and 6, and KIR2DL2
recognizes HLA-Cw1, 3, 7, and 8 (Winter and Long, 1997;
Boyington et al, 2000; Fan et al, 2000). Both classes of KIR receptor
have an inhibitory form with a long cytoplasmic tail (KIR2DL), as
well as an activating form with a short cytoplasmic tail (KIR2DS).
This raises the possibility that HLA-C associations of psoriasis may
be mediated by activating natural killer cell receptors.
IFN-g may mediate the induction of psoriasis by either natural
killer cells, or T lymphocytes (Nickoloff, 2000a). IFN-g injection
induces psoriasis at injection sites (Fierlbeck et al, 1990), and both
IFN-g mRNA (Barker et al, 1991), and IFN-g inducible protein 10
are present in psoriatic plaques (Gottlieb et al, 1988; Smoller et al,
1990). Skin in®ltrating T cells produce IFN-g both following in vitro
stimulation (Nielsen et al, 1998; Austin et al, 1999; Brown et al,
2000), and when freshly isolated from skin lesions (Szabo et al,
1998). Keratinocytes may play a part in promoting IFN-g
production by lymphocytes. Human keratinocytes are capable of
secreting IL-18 following activation (Naik et al, 1999). IL-12 is
present at increased levels in psoriatic lesional skin (Yawalkar et al,
1998), and IL-18 synergizes with IL-12 to induce IFN-g produc-
tion by T cells (Tominaga et al, 2000). Both normal and psoriatic
epidermis express IFN-g receptors, with possibly increased
suprabasal expression of IFN-g receptors in psoriatic skin (van
den Oord et al, 1995). Furthermore, IFN-g treatment of human
skin explants in vitro induces a proliferative epidermal phenotype
with expression of K16, similar to the changes of psoriasis (Wei et
al, 1999). Natural killer cell lines from normal and psoriatic
patients, used in this study, produced similar levels of IFN-g,
Figure 5. Normal (nonpsoriasis) donor skin
grafted to beige-SCID mice and injected
with natural killer cells. Results are shown for
two donors, not injected, injected with
autologous (normal) natural killer cells, allogeneic
psoriasis natural killer cells, and allogeneic normal
(nonpsoriasis) natural killer cells. Scale bar: 50 mm.
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suggesting that the tissue response is the critical factor in the
generation of psoriasis.
Psoriasiform epidermal changes are seen in many conditions,
including the response to dermatophyte infection. Resistance to
dermatophyte infection is partially mediated by cellular immunity
(Green et al, 1983; Calderon and Hay, 1984; MacCarthy et al,
1994), but the mechanism has not been delineated. It is possible
that increased epidermal proliferation, as seen in psoriasiform
epidermal hyperplasia, is a lymphocyte-mediated defense mechan-
ism whereby the epidermis proliferates faster than the dermato-
phyte can invade, thereby shedding the dermatophyte. Psoriasis
may represent an alteration of this normal physiologic response.
Psoriasis induction by lymphocytes with natural killer receptors
appears to be dependent upon the source of skin. Natural killer cells
from nonpsoriatic control donors induced psoriasiform dermatitis
changes rather than true psoriasis. This suggests psoriasis results
from a cutaneous defect that is triggered by an autoimmune
activation. Superantigen was not necessary for the induction of
psoriatic lesions with natural killer cells.
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